Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852 · Glaukos Corporation

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title

Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

About this study

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Eligibility criteria

Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Study design

Enrollment target: 510 participants

Allocation: randomized

Masking: triple

Age groups: adult, older_adult

Timeline

Starts: 2026-02-17

Estimated completion: 2032-03

Last updated: 2026-03-30

Interventions

Drug: Gen 2 Travoprost Intracameral ImplantDrug: Timolol eye drops 0.5%Procedure: Sham ProcedureOther: placebo eye drops

Primary outcomes

• Intraocular pressure (IOP) (3 months)

Sponsor

Glaukos Corporation · industry

Contacts & investigators

ContactStudy Director · contact · ClinicalResearch@glaukos.com · 949-739-8749

All locations (1)

Glaukos Investigative SiteRecruiting

Dothan, Alabama, United States

View on ClinicalTrials.gov ↗Find similar trials